Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Unicycive Therapeutics (UNCY) has shared an update.
Unicycive Therapeutics, Inc. has announced significant success in their Oxylanthanum Carbonate (OLC) UNI-OLC-201 clinical trial, meeting both primary and secondary endpoints. This breakthrough was shared in a press release and during a corporate presentation, signaling potentially positive impacts for the company’s future and stirring interest among investors and market watchers.
See more data about UNCY stock on TipRanks’ Stock Analysis page.
